Asia Pacific Liver Cancer Drug Market Size & Outlook, 2030

Revenue, 2021 (US$M)

$338.3

Forecast, 2030 (US$M)

$1,453.6

CAGR, 2022 - 2030

17.6%

Report Coverage

Asia Pacific

Asia Pacific liver cancer drug market, 2018-2030 (US$M)

Related Markets

Global Liver Cancer Drug Industry Outlook

North America Liver Cancer Drug Market Outlook

Europe Liver Cancer Drug Market Outlook

Latin America Liver Cancer Drug Market Outlook

MEA Liver Cancer Drug Market Outlook

Asia Pacific liver cancer drug market highlights

The Asia Pacific liver cancer drug market generated a revenue of USD 338.3 million in 2021.
The market is expected to grow at a CAGR of 17.6% from 2022 to 2030.
In terms of segment, targeted therapy was the largest revenue generating drug class in 2021.
Targeted Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.

Asia Pacific data book summary

Market revenue in 2021	USD 338.3 million
Market revenue in 2030	USD 1,453.6 million
Growth rate	17.6% (CAGR from 2021 to 2030)
Largest segment	Targeted therapy
Fastest growing segment	Targeted Therapy
Historical data covered	2018 - 2020
Base year for estimation	2021
Forecast period covered	2022 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Targeted Therapy
Key market players worldwide	Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, Merck KGaA, Exelixis Inc

Other key industry trends

In terms of revenue, Asia Pacific region accounted for 15.5% of the global liver cancer drug market in 2021.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 1,453.6 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Liver Cancer Drug Market Scope

Liver cancer drug market segmentation & scope

Drug Class

Targeted Therapy

Immunotherapy

Chemotherapy

Regions

Latin America

Europe

North America

Middle East & Africa

Asia Pacific

Countries

U.S.

Canada

Spain

Sweden

Norway

Italy

Germany

France

Denmark

Argentina

Brazil

Mexico

UAE

South Africa

Saudi Arabia

Kuwait

Thailand

South Korea

Japan

India

China

Australia

Liver Cancer Drug Market Companies

Name	Profile	# Employees	HQ	Website

Asia Pacific liver cancer drug market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer drug market will help companies and investors design strategic landscapes.

Targeted therapy was the largest segment with a revenue share of 100% in 2021. Horizon Databook has segmented the Asia Pacific liver cancer drug market based on targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Asia Pacific liver cancer drug market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific liver cancer drug market databook

Our clientele includes a mix of liver cancer drug market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific liver cancer drug market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific liver cancer drug market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list